

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## Essential Oil Encapsulations: Uses, Procedures, and Trends

**Hamid Majeed<sup>a</sup>, Yuan-Yuan Bian<sup>a</sup>, Barkat Ali<sup>a</sup>, Anjum Jamil<sup>b</sup>, Usman Majeed<sup>b</sup>, Qaiser Farid Khan<sup>c</sup>, Khalid Javed Iqbal<sup>d</sup>, Charles F Shoemaker<sup>e</sup> and Zhong Fang<sup>a</sup>**

<sup>a</sup>Key Laboratory of Food Colloids and Biotechnology, Ministry of Education, School of Food Science and Technology, Jiangnan University, Wuxi 214122, P.R. China.

1 <sup>b</sup>Department of veterinary sciences, University of Agriculture Faisalabad, Pakistan

2 <sup>c</sup>Microbial Electro-chemistry Research Group, Swette Centre for Environmental  
3 Biotechnology Biodesign Institute Arizona State University, Tempe, AZ.

4 <sup>d</sup>Department of Life Sciences, The Islamia University of Bahawalpur, Pakistan

5 <sup>e</sup>Department of Food Science and Technology, University of California, Davis, CA 95616,  
6 USA

7

8 <sup>a</sup> **Corresponding author:**

9 **Hamid Majeed**

10 Key Laboratory of Food Colloids and Biotechnology,  
11 Ministry of Education, School of Food Science and  
12 Technology, Jiangnan University,  
13 Wuxi 214122, P.R. China.  
14 Tel. +8618351570870.

15 **E-mail address:** [hamid.maieedju@yahoo.com](mailto:hamid.maieedju@yahoo.com)

## Essential Oil Encapsulations: Uses, Procedures, and Trends

Hamid Majeed, Yuan-Yuan Bian, Barkat Ali, Anjum Jamil, Usman Majeed, Qaiser Farid Khan, Khalid Javed Iqbal, Charles F Shoemaker and Zhong Fang

16 **Abstract:**

17 Recently there has been an increased interest towards the biological activities of essential oils  
18 (EOs). However, EOs are unstable and susceptible to degradation when exposed to  
19 environmental stresses like oxygen, temperature, and light. Therefore, attempts have been  
20 made to preserve them through encapsulation in various colloidal systems such as  
21 microcapsules, nanospheres, nanoemulsions, liposomes, and molecular inclusion complexes.  
22 This review focuses on various techniques used for the encapsulation of EOs, potential  
23 applications in food, and their behaviours/trends after encapsulation. The encapsulation  
24 efficiency, particle size, and physical stability of EOs encapsulated in colloidal systems is  
25 dependent on the kind of technique and the type and concentration/ratio of emulsifier/wall  
26 material used. Moreover, the benefits associated after encapsulation, namely bioavailability,  
27 controlled release, and protection of EOs against environmental stresses are discussed. The  
28 applications of encapsulated EOs are also summarized in this review. Encapsulated EOs are  
29 promising agents that can be used to increase the anti-microbial, antifungal, antiviral, and  
30 pesticidal activities of EOs in real food systems, to study their action mechanism, and to  
31 provide nonlethal therapeutic agents to treat several diseases.

32 **Keywords:** Essential oils, Antimicrobial, Bioavailability, Therapeutic agents and Colloidal  
33 systems.

34

35

- 36 1. Introduction
- 37 2. Essential oil and their properties
- 38 3. Encapsulation of essential oils: Techniques/strategies
- 39 3.1 Chemical Procedures
- 40 3.2 Physicochemical Procedures
- 41 3.3 Mechanical Procedures
- 42 3.4 Other Encapsulation Methods
- 43 3.5 Emulsifiers/wall materials used for essential oils
- 44 3.6 Encapsulation and its benefits
- 45 3.6.1 Encapsulation of essential oils for controlled release
- 46 3.6.2 Encapsulation of essential oils for controlled release
- 47 3.6.3 Encapsulation of essential oils for increased stability
- 48 4. Encapsulated essential oils applications
- 49 5. Encapsulated essential oils behaviours/trends
- 50 6. Conclusions and Future Perspectives

## 51 **1. Introduction**

52 EOs are diverse group of natural aromatic compounds isolated mostly from non-  
53 woody plant materials by hydro-distillation, solvent-solvent extraction, and liquid CO<sub>2</sub>  
54 extraction<sup>1</sup>. They contain terpenoids, especially monoterpenes (C<sub>10</sub>), sesquiterpenes (C<sub>15</sub>),  
55 and diterpenes (C<sub>20</sub>), along with a variety of aliphatic hydrocarbons (low molecular weight),  
56 acids, alcohols, aldehydes, and esters.<sup>2,3,4</sup> They are characterized by main constituents present  
57 in higher concentrations rather than components in trace quantities. For example, EOs of  
58 clove contains 85% eugenol, 10-12% eugenol acetate, and these determine its biological  
59 activity.<sup>5</sup> Due to these versatile compounds EOs possess bactericidal, fungicidal, antioxidant,  
60 virucidal, and anticarcinogenic properties. EOs have already been utilized to control bacterial

61 and fungal contaminations.<sup>6,7,8</sup> Fu and others (2007)<sup>6</sup> evaluated the bactericidal and fungicidal  
62 potential of clove and rosemary EOs alone and in combination. They found significant  
63 inhibition of *S.epidermidis*, *E.coli*, and *C.albicans* at MIC values of 0.062- 0.500% (v/v),  
64 0.125-1.00% (v/v) for clove and rosemary EOs, respectively. Similarly, other researchers  
65 have also used EOs as antibacterial and antifungal agents.<sup>7,8,9,10,11,12,13</sup> Gortzi and others  
66 (2008)<sup>14</sup> used *Myrtus communis* extract to inhibit the oxidation of sunflower oil. The results  
67 showed considerable reduction in oxidation at 160 ppm, and the antioxidant activity of  
68 extracts further improved when encapsulated in liposome. EOs possess volatile constituents  
69 which are sensitive to oxygen, light, humidity, and heat. To increase their stability and  
70 functional performance EOs can be encapsulated.

71 Encapsulation has been widely used for protection, target delivery, and enhanced  
72 biological functions of bioactive compounds.<sup>15,16,17</sup> Wang and others (2009)<sup>17</sup> prepared  
73 carvacrol loaded microcapsules, designed to target the intestine for enhanced antimicrobial  
74 activity and increased bioavailability. They found < 20% oil released in stomach and rest was  
75 completely released in intestine. Similarly, variety of researchers reported sustained release  
76 characteristics of EOs after encapsulation in different matrices<sup>15,16,18,19,20</sup>. Encapsulation not  
77 only provides controlled release, but also increased the bioavailability of bioactive  
78 compounds/drugs. The same trend was observed, when different EOs constituents  
79 (peppermint oil, eugenol, carvacrol and thymol) were nanoencapsulated, which resulted in  
80 enhanced antimicrobial activity compared to bulk oil.<sup>21,22</sup> To achieve these benefits, EOs  
81 have been encapsulated by using various chemical, physicochemical and mechanical  
82 procedures. Among these liposomes,<sup>14</sup> molecular inclusion,<sup>23,24</sup> coacervation and complex  
83 coacervation,<sup>25,26</sup> spray drying,<sup>27</sup> emulsification,<sup>21,28</sup> ionic gelation<sup>29</sup> and emulsion extrusion<sup>17</sup>  
84 have been used by many researchers to encapsulate EOs. Encapsulation consists of two  
85 important things namely core (bioactive) & wall material/emulsifier (that protects bioactive).

86 The latter is of great importance because the stability, release behavior of core (bioactive)  
87 depends on its physiochemical nature, and further on type, and parameters of encapsulation  
88 technique. Different types of protein,<sup>26,30</sup> polysaccharide<sup>21,31</sup> and synthetic<sup>22,32</sup>  
89 emulsifiers/wall materials have been used to encapsulate the EOs/constituents. This article  
90 will focus on various procedures employed for EOs encapsulation, benefits after entrapment,  
91 uses in food, and their trends.

## 92 **2. Essential oils and their properties**

93 EOs are complex natural, volatile aromatic compounds, characterized by two or three  
94 major components at fairly high concentrations (20–70%) compared to other components  
95 present in trace amounts. Biological activities of EOs are mainly due to main components  
96 that are present in high concentration. For example, *Artemisia alba* EO possesses camphor 24%,  
97 while *Mentha piperita* contains menthol and menthone 59% and 19%, respectively. Because  
98 of these components, EOs have been largely employed for their well-known antibacterial,  
99 antifungal, antioxidant, and anticarcinogenic applications. Walsh and others (2003)<sup>8</sup> reported  
100 antimicrobial properties of natural bactericidal compounds eugenol, thymol, triclocarban  
101 (TCC), and didecyldimethylammonium chloride (DDDMAC) against *E.coli*, *S. aureus* and *P.*  
102 *aeruginosa*. Eugenol, thymol, and alkyl dimethyl amine oxides (ADMAO) were effective  
103 against *E.coli*, *S. aureus*, while TCC showed activity only against *S.aureus*. The observed  
104 minimum inhibitory concentration values (MIC) of eugenol, and thymol against *E.coli*,  
105 *S.aureus* and *P.aeruginosa* were 0.05, 0.1 and > 0.1% (v/v), respectively. Strong inhibitory  
106 action of eugenol, carvacrol, thymol, diacetyl, and cinnamic acid against *E. sakazakii* has also  
107 been confirmed.<sup>33</sup> Fu and others (2007)<sup>34</sup> suggested inhibition of *S. epidermidis*, *S.aureus*, *B.*  
108 *Subtilis*, *E.coli*, *P. Vulgaris*, *P.aeruginosa*, *C.albicans* and *A.niger* by clove and rosemary  
109 EOs alone and in combination. The MIC values for clove & rosemary EOs were in the range

110 of 0.062% to 0.5% (v/v) and 0.125% - 1% (v/v). Bactericidal action of EOs have also been  
111 confirmed by many studies.<sup>9,10,11,13</sup>

112 EOs possess promising antifungal activity, and have potential to replace synthetic  
113 preservatives as revealed by many researchers.<sup>35,36,37,38,39,40,41</sup> Bansod and Rai (2008)<sup>42</sup>,  
114 suggested fungicidal action of *Cymbopogon martini*, *Eucalyptus globules*, and *Cinnamomun*  
115 *zylenicum* EOs against *A. niger*, and *A. fumigatus*. The MIC values were 0.06, 0.12, and  
116 0.12% (v/v), respectively. Amiri and others (2008)<sup>43</sup>, reported eugenol (2 mg/ml) induced  
117 mycelial growth inhibition of *P.vagabunda*, *P. expansum*, *Bortrytiscinerea*, and *M.*  
118 *fructigena*. The average growth inhibition varied between 88.6- 90% at 4°C and 72.5-84.4%  
119 at 20°C, respectively. EOs also possess antioxidant activity as evidenced by many  
120 studies.<sup>44,45,46,47,48,49,50</sup> Viuda-martos and others (2010)<sup>51</sup> used EOs for in vitro evaluation.  
121 Among five spice EOs oregano, thyme, rosemary, sage, and clove, clove EO showed strong  
122 antioxidant potential as it inhibited (98.74%) DPPH radical. Antioxidant potential of cumin  
123 (*Cuminum Cyminum* L.) stem, leaves, and flowers EOs have also been reported. They found  
124 that cumin flower acetone extract was more effective antioxidant interms of DPPH radical  
125 scavenger, lipid peroxidation inhibitor, and reducing agent with IC50 value 4, 32 and 8  
126 µg/ml, respectively.<sup>52</sup>

127 EOs have been also utilized as potential source of anticarcinogenic  
128 agents.<sup>53,54,55,56,57,58,59,60</sup> The EOs from lemon grass (*Cymbopogon flexuosus*), sage (*Salvia*  
129 *officinalis*), katafa (*Cedrelopsis grevei*), and bugleweed (*Lycopus lucidus*) have been reported  
130 to be cytotoxic to human cancer cell lines.<sup>61,62,63</sup> Sylvestre and others (2006)<sup>64</sup>, found  
131 significant tumor growth reduction of human lung carcinoma cell line A-549 and human  
132 colon adenocarcinoma cell line DLD-1, when treated with *Croton flavens* leaf EO. The GI50  
133 values were 27±4 µg/ml for A-549 and 28±3 µg/ml for DLD-1, respectively. Similarly,  
134 Ashour (2008)<sup>65</sup> reported anticarcinogenic potential of *Eucalyptus sideroxylon* and

135 *Eucalyptus torquata* leaf, stem, and flower EOs against human hepatocellular carcinoma cell  
136 line (HEPG2), and human breast adenocarcinoma cell line (MCF7). In spite of all these  
137 characteristics, EOs have certain limitations such as low water solubility, high volatility, and  
138 strong odor that limit their applications in food and pharmaceutical industry. To overcome  
139 such barriers, EOs can be encapsulated to retain their stability, flavor retention, and  
140 functional properties.

141

### 142 **3. Encapsulation of essential oils (EOs): Techniques/strategies**

143 Encapsulation of EOs has been carried out by variety of chemical,<sup>15</sup>  
144 physicochemical<sup>24</sup> and mechanical procedures.<sup>21,22,28,30</sup> Commonly used procedures to  
145 encapsulate EOs are summarized in Figure: I.

#### 146 **3.1 Chemical Procedures**

147 Among chemical approaches liposomes have been widely used for the encapsulation  
148 of EOs. Liposomes are normally prepared by mixing lipids in organic solvents and  
149 subsequent drying either by rotary evaporator, spray drying or by lyophilization.  
150 Phospholipids have typically been used for the preparation of liposomes. For thymol and  
151 carvacrol egg L- $\alpha$  phosphatidylcholine & cholesterol were mixed in methanol, solvent  
152 removed at 35°C under nitrogen stream & the lipid film obtained was hydrated to prepare  
153 multilamellar vesicles (MLV) from unilamellar vesicle. A total of 1.07 mg carvacrol was  
154 added in liposomes and the encapsulated percentage was 4.16% (0.045mg). The liposomes  
155 incorporated carvacrol & thymol showed enhanced antimicrobial activity and its long term  
156 retention favored its stability in liposomes as evident from stability study.<sup>71</sup> In another study  
157 *Myrtus communis* extract was incorporated in liposomes prepared by L- $\alpha$   
158 phosphatidylcholine & cholesterol mixed in chloroform-methanol solution to determine the  
159 antioxidant activity. Whereas, Phosphatidylglycerol was replaced with L- $\alpha$



160 phosphatidylcholine for antimicrobial activity determination. The liposomes prepared were  
161 spherical in shape and the size was in the range of 270-300 nm.<sup>14</sup> Similarly, Sinico and others  
162 (2005)<sup>32</sup> prepared MLV of *A.aborescence* EO (2.5 mg/ml) using soya phosphatidylcholine  
163 in chloroform. They reported less incorporation of EO in Brij30 based vesicles, while soya  
164 phospholipid vesicles entrap 60-74% of *A.aborescence* EO with size in the range of 70-150  
165 nm. The liposomes incorporated *A.aborescence* oil significantly reduced herpes simplex  
166 virus-1 (HSP-1) at 100 ug/ml while free/unencapsulated oil at similar dose showed poor  
167 activity. This result also confirmed the stability of oil in liposomes with increased bioactivity.  
168 In addition to chemical procedures various researchers used physicochemical procedures to  
169 encapsulate EOs<sup>25,26</sup>.

### 170 3.2 Physicochemical Procedures

171 Coacervation is a physico-chemical process that involves phase separation of one or  
172 more hydrocolloids from solution and subsequent deposition of newly formed coacervate  
173 phase around the active ingredient suspended in the same reaction media. Rosmarinus and  
174 thymus EOs were dispersed in 10% gelatin solution prepared at 40°C, mixture was emulsified  
175 using high shear mixer with subsequent addition of sodium sulphate (20% wt/wt) to obtain  
176 coacervate phase at 5°C under continuous stirring for 1 hour. Further, glutaraldehyde  
177 (1mmol/g gelatin) was added at pH 8 under stirring at 750 rpm at 5°C for 3 hours and finally  
178 microparticles were filtered and freeze dried. The microcapsules prepared were spherical with  
179 an average diameter of 60µm and retained 75% of oil in microcapsules. However, significant  
180 increase in mortality of Indian meal moth (*P. interpunctella*) was recorded as concentration of  
181 microcapsules increased in the diet.<sup>26</sup> Similarly, citronella oil was also encapsulated by  
182 simple coacervation as described earlier except formaldehyde solution (37% v/v) that was  
183 used to rigidize citronella oil entrapped gelatin microcapsules. The microcapsules showed  
184 slow release of citronella oil (CO) and after 10 hours 70% was released. The results of this

185 study showed sustained release and protection of oil from environmental factors.<sup>31</sup> In another  
186 study, lavender oil microcapsules were prepared using complex coacervation of collagen  
187 hydrolysate (CH), chitosan (C) crosslinked with glutaraldehyde. Briefly, both CH (5 g) and C  
188 (2.5 g) were dissolved separately in distilled water (100 ml), heated until transparency  
189 achieved. Both CH-C solution (1/0.0, 0.75/0.25, 0.5/0.5 & 0.25/0.75) were mixed under  
190 stirring (800 rpm) at 30°C. After that temperature increased to 42°C, lavender oil (2-10ml)  
191 was added drop wise and coacervate formed by the addition of sodium sulphate (10% wt/v) at  
192 pH 7. Further microcapsules were cross-linked using glutaraldehyde (0.1-0.3 mmol/g) under  
193 stirring at 42°C for 6-8 hours, temperature reduced to 30°C and microcapsules washed with  
194 0.1% Tween80 solution to remove surface oil & finally freeze dried. The microcapsules  
195 prepared were spherical and encapsulation efficiency was 36.84-73.73%.<sup>67</sup> Complex  
196 coacervation was also used to prepare camphor oil loaded microcapsules of gelatin blended  
197 with gum arabic and further fabricated with polystyrene. The microcapsules showed  
198 encapsulation efficiency between 80-100% and particle sizes were 85.7, 167.2 & 294.7µm  
199 respectively.<sup>25</sup>

200 Ayala-Zavala and others (2008)<sup>23</sup> prepared cinnamon and garlic oil loaded  
201 microcapsules using molecular inclusion/ $\beta$ -cyclodextrin inclusion complex method. Briefly,  
202  $\beta$ -cyclodextrin (50 g) was dissolved in ethanol-water mixture (1:2) at 55 °C, after that each  
203 EO dissolved in ethanol (10% w/v) was slowly added to warm  $\beta$ -cyclodextrin solution in  
204 variable weight ratios (0:100, 4:96, 8:92, 12:88 & 16:84). Finally, resultant mixture was  
205 stirred without heating for 4 h and precipitated oil-  $\beta$ -cyclodextrin microcapsules were  
206 filtered and dried in convection oven (50°C). The microcapsules of both cinnamon & garlic  
207 oil showed encapsulation efficiency of 94.82, 93.76%, respectively and were effective against  
208 *A.alternata* fungus. Choi and others (2009)<sup>24</sup> prepared eugenol loaded microcapsules using  $\beta$ -  
209 cyclodextrin & 2-hydroxyl propyl (2HP)  $\beta$ -cyclodextrin by molecular inclusion method. They

210 reported higher encapsulation efficiency of eugenol-  $\beta$ -cyclodextrin (90.9%) than eugenol-  
211 2HP  $\beta$ -cyclodextrin (89.1%) and confirmed that hydrophilic chain of 2- hydroxyl propyl  
212 group in 2HP  $\beta$ -cyclodextrin was not efficient for the inclusion of lipophilic compounds like  
213 eugenol. Another research group encapsulated flax seed oil in  $\beta$ -cyclodextrin inclusion  
214 complexes in variable ratios (5:95-20:80 wt/wt). They obtained maximum load (95.8 mg of  
215 oil/g  $\beta$ -cyclodextrin) of flaxseed oil at 20:80 ratio and further no change in the composition of  
216 oil was observed after inclusion in  $\beta$ -cyclodextrin as evidenced from gas chromatography  
217 results. These results showed protection of eugenol and favored its encapsulation in inclusion  
218 complexes as suitable approach.<sup>81</sup> PO,<sup>19</sup> lemon oil<sup>82</sup> in  $\beta$ -cyclodextrin inclusion complexes  
219 have also been encapsulated as described earlier. Hill and others (2013)<sup>83</sup> prepared  $\beta$ -  
220 cyclodextrin inclusion complexes of eugenol, trans-cinnamaldehyde, clove extract, cinnamon  
221 bark extract and eugenol: trans-cinnamaldehyde via freeze drying. The particle sizes were in  
222 the range of 0.86 – 2.00  $\mu\text{m}$ , showed spherical morphology with entrapment efficiency of  
223 41.7-84.7%. They confirmed inhibitory action of microcapsules against *S. enterica*,  
224 *Typhimurium* & *L. innocua* but unencapsulated/free oil and extracts showed poor inhibition at  
225 same concentrations. These results showed better retention and protection of lipophilic  
226 compounds in inclusion complexes.

### 227 3.3 Mechanical Procedures

228 Among these spray drying is the low cost, commercial process which is mostly used  
229 for the encapsulation of EOs. In spray drying, core material is dispersed in polymer solution,  
230 and sprayed into a hot air chamber. Arana-Sanchez and others<sup>74</sup> spray dried OEO emulsion  
231 prepared using  $\beta$  cyclodextrin, fed at room temperature with an inlet air temperature of  
232 105°C, and pump flow rate was 1.1 ml/min. Microcapsules showed spherical to ovoid shape  
233 with size in the range of 0.71-20 $\mu\text{m}$ , 1.42- 28.14 $\mu\text{m}$ , and 1.07-38 $\mu\text{m}$ , respectively. The  
234 formulation with bigger size showed increased encapsulation efficiency (81.03%) compared

235 to smaller sized capsules (0.71-20  $\mu\text{m}$ ) with 53.90%. Thymol loaded emulsion prepared with  
236 whey protein-maltodextrin conjugate was also spray dried with an inlet air temperature of  
237 150°C, compressed air pressure of 600 kpa, air flow rate of 35  $\text{m}^3/\text{h}$ , and feed rate was 6.67  
238 ml/min. The encapsulation efficiency was 73.8% - 82.8% at 10% volume fraction of oil  
239 phase, but reduced to 67.6% when oil phase fraction increased to 30%. They also reported  
240 loss of thymol due to inlet temperature that was equivalent to its vapor pressure (8.0 kpa), and  
241 concomitant loss of capsule shape i.e, ruptured wall that happened during spray drying as  
242 evident from AFM images<sup>75,76</sup>. Another research group prepared powdered eugenol nano-  
243 dispersions by spray drying at 6.67 ml/min feed rate and outlet temperature was 80-90°C.  
244 They reported stable and transparent nano-dispersions having small particle size.<sup>75,76</sup> Basil oil  
245 emulsion emulsified with gum arabic was spray dried using emulsion feeding rate of 0.7 L/h,  
246 drying temperature of 180°C, and vapor pressure of 0.4 MPa.<sup>77</sup> The droplets mean diameter  
247 was 1.17 – 2.87 $\mu\text{m}$ , and oil retention varied from 56.43- 88.28%. Baranauskiene and others<sup>30</sup>  
248 spray dried Peppermint oil (15.25% wt/wt) dispersed in wall material solutions of n-octenyl  
249 succinic anhydride modified starches. The dispersions were dried in Buchi mini spray drier at  
250 inlet air temperature of  $200 \pm 10^\circ\text{C}$ , outlet temperature of  $120 \pm 10^\circ\text{C}$ , and compressor  
251 pressure of 400 mm/H<sub>2</sub>O. They also reported increased retention of oil (39.2-97.4%) was  
252 associated with small size droplets compared to bigger ones. On the other hand, more oil  
253 evaporated/lost during atomization as modified starches take longer time for film formation  
254 around droplets during spray drying. Clove extract (2.5g) emulsion prepared with  
255 maltodextrin (12 g) and gum arabic (6 g) was spray dried at inlet & outlet temperature of  
256 150°C & 86°C, respectively. The powder particles showed (1-15 $\mu\text{m}$ ) shriveled morphology  
257 with yield percentage of 62%, when air flow, emulsion feed rate, and atomization pressure  
258 were kept at 40 mm, 6.67 ml/min, -45mbar, respectively. Rosemary EO emulsified with whey  
259 protein isolate, and inulin was fed into spray dryer at 0.9 L/h with an inlet temperature of

260 170°C to prepare encapsulated powders. The microencapsulation efficiency was 28.97-  
261 38.34%, and the retention of oil was more when whey protein, and inulin concentration was  
262 3:1 and 1:1. However, no increase in oil retention was observed with higher inulin  
263 concentration. They reported increased efficiency of EO during spray drying that was  
264 dependent on wall material type and its emulsifying capability.<sup>78</sup> In another study rosemary  
265 EO dispersed in gum arabic solution (1:4 oil/wall) was spray dried to prepare encapsulated  
266 powder.<sup>79</sup> Spray drying was done at an inlet temperature of 171°C, feed rate of 0.92 L/h, and  
267 atomizing air pressure was kept at 40 L/h. They reported efficient drying at higher inlet  
268 temperature, and increased wall material concentration, which resulted in more powder  
269 recovery. They observed loss of oil content from particles due to volatilization during drying  
270 by atomization because of delay in the formation of semi permeable membrane when carrier  
271 concentration was low. However, maximum oil retention was 36.95% when wall material  
272 (gum arabic) concentration was 19.3%. Similarly, Beirao-da-costa and others (2013)<sup>18</sup> spray  
273 dried OEO emulsion, the capsules prepared were in the range of 3-4.5 µm and some capsules  
274 represent ruptured wall due to high inlet temperature. Najafi and others (2011)<sup>80</sup> compared  
275 spray and freeze drying method for the encapsulation of cardamom oil using HI CAP 100 and  
276 skim milk powder as wall materials. The spray drying retained more volatiles (91-94%) than  
277 freeze drying (84-86%) and microcapsules prepared were of high quality compared to freeze  
278 dried microcapsules. However, in case of skim milk powder, microcapsules particle size  
279 (13.97-19.91 µm) was smaller than HI CAP 100 (15.41-21.87 µm) but, former released  
280 volatile contents much faster during drying than later one. Therefore, spray drying was  
281 recommended as suitable method for the encapsulation of EOs.

282 Similarly, various researchers used high energy emulsification approach for the  
283 generation of EOs loaded nanoemulsions has been carried out by many researchers. For  
284 example, Liang and others (2012)<sup>21</sup> for the preparation of PO loaded nanoemulsion, blended

285 PO with medium chain triglyceride (MCT), and mixed with purity gum 2000 solution 12%  
286 (w/w) to prepare coarse emulsion using Ultra Turax (a high speed blender). Finally, coarse  
287 emulsions passed through high pressure homogenizer at 150Mpa, and 5 processing cycles,  
288 showed particle size <200 nm and were effective against *S.aureus* & *L.monocytogenes* till 24  
289 hours at 0.25% (v/v) concentration. They confirmed similar composition of PO components  
290 before and after encapsulation. The long term inhibition of bacterial growth by PO  
291 nanoemulsions and their better protection promoted high energy emulsification a suitable  
292 method for encapsulation of EOs. Similarly, another research group prepared D-limonene,  
293 Cinnamaldehyde and carvacrol loaded nanoemulsions (130-293 nm) using soy lecithin (3%),  
294 pea proteins (3%), sugar ester (1%) and Glycerol monooleate with Tween 20 (0.5:0.5%) as  
295 emulsifying agents. The formulations with glycerol monooleate with Tween 20 showed  
296 prolonged bactericidal action against *S.cerevisiae*, *E.coli* & *L.delbrueckii* because of more  
297 availability of antimicrobial compound by this emulsifier compared to other emulsifiers. D-  
298 limonene & terpenes mixture from *Melaleuca alternifolia* based nanoemulsions (74-365 nm)  
299 were also prepared using Tween 20 & glycerol monooleate, soy lecithin and cleargum  
300 individually as emulsifiers. Soy lecithin based emulsions formulations of D-limonene &  
301 terpene mixture were efficient and delayed growth of *L.delbrueckii* for 5 days in orange & 2  
302 days in pear juice compared to control when added at concentration of 1 g/L.<sup>28</sup> Terjung and  
303 others (2012)<sup>22</sup> also reported preparation of eugenol and carvacrol loaded nanoemulsions  
304 using high pressure homogenization technique. They observed antimicrobial activity of  
305 eugenol and carvacrol loaded variable particle sized emulsions (80, 200, 1000 and 3000nm)  
306 against *E.coli* & *L.innocua*. They reported complete killing of bacterial cells when treated  
307 with bigger particle size (3000 nm) due to more concentration of antimicrobial compound  
308 and vice versa happens with smaller particle size (80 nm). Rosemary EO loaded emulsions  
309 prepared by high pressure homogenization was stable for 50 days at ambient conditions.<sup>84</sup>

310 Chang and others (2012)<sup>85</sup> prepared thyme oil (10% v/v) loaded nanoemulsions with average  
311 particle size of (160, 170 nm) using high pressure homogenization. They reported decreased  
312 antimicrobial efficacy because of increased concentration of ripening inhibitors type (corn oil  
313 or medium chain triglyceride MCT oil) in lipid phase and when 70% ripening inhibitor was  
314 added in lipid phase the minimum inhibitory concentration against *Zygosaccharomyces bailii*  
315 containing corn & MCT oil were 750 and 3000 µg/ml, respectively. These results showed  
316 physical stability of thyme oil in nanoemulsions droplets but decreased antimicrobial activity  
317 was due to partition coefficient. Vegetable,<sup>86</sup> soybean,<sup>87</sup> corn or octadecane,<sup>88</sup> castor,<sup>89</sup>  
318 citronella, basal & vetiver oil<sup>90</sup> based nanoemulsions have also been prepared by using high  
319 pressure homogenization technique.

#### 320 3.4 Other encapsulation methods

321 Eugenol and carvacrol grafted chitosan nanoparticles were prepared via Schiff base  
322 reaction.<sup>29</sup> Briefly, chitosan nanoparticles (CH-NPs) were prepared using ionic gelation  
323 method. For this 0.5% w/v chitosan in 1% v/v acetic acid at pH 4.1, TTP solution (2.5 mg/ml)  
324 was added drop wise in chitosan solution under stirring at 10000 rpm, separated by  
325 centrifugation and were freeze dried. Further, eugenol and carvacrol aldehydes were grafted  
326 on CH-NPs via Schiff base reaction. A 30ml methanol, 100 mg CH-NPs with excess of  
327 eugenol & carvacrol aldehydes and reaction mixture was refluxed for 48 hours. Finally,  
328 eugenol and carvacrol grafted nanoparticles were separated by centrifugation and vacuum  
329 dried at 42°C for 12 hours. Among eugenol (235 nm) & carvacrol (260 nm) grafted CH-NPs,  
330 eugenol grafted nanoparticles showed antioxidant activity at lower EC<sub>50</sub> (2.6 mg/ml) value  
331 than carvacrol grafted nanoparticles (>4.0 mg/ml). On the other hand, eugenol grafted CH-  
332 NPs showed higher antimicrobial efficacy than carvacrol grafted CH-NPs. In another  
333 research, OEO was encapsulated in chitosan nanoparticles by two step process i.e, oil in  
334 water o/w emulsion and ionic gelation of chitosan with sodium tripolyphosphate (TPP). In

335 this chitosan (1% w/v) in acetic acid (1% v/v) solution was stirred and Tween 80 was added  
336 to get homogenous mixture under stirring at 42°C for 2 hours. After that OEO (0.04, 0.08,  
337 0.16 & 0.32 g) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (4ml) and dropped in chitosan solution during  
338 homogenization to prepare oil in water emulsion. TTP solution was then added drop wise into  
339 agitated emulsions till 40 minutes. Finally, nanoparticles were centrifuged (9000 g),  
340 suspension was sonicated in ice bath (0.7 s working & 0.3 s rest) and freeze dried at -35°C for  
341 72 hours. The prepared nanoparticles were spherical (40-80 nm) and the encapsulation  
342 efficiency was 21- 47%.<sup>20</sup> In the orifice method citronella oil loaded microcapsules were  
343 prepared as follows, 0.5 wt.% yellow dye was added in citronella oil, citronella oil (2 ml) was  
344 added in chitosan solution (0.2, 0.5, 1 & 1.5%) under stirring. After that 0.1-1.5wt% NaOH  
345 was added slowly and the prepared microcapsules were centrifuged to remove excessive  
346 material and kept in 5 wt. % natural coconut oil for 10 days. Finally microcapsules were  
347 vacuum oven dried at 30°C for overnight. They concluded that encapsulation efficiency  
348 affected by chitosan concentration and when these were 0.5, 1 & 1.5 % the encapsulation  
349 efficiencies were 98.2, 95.8 and 94.7%, respectively.<sup>15</sup> Carvacrol loaded microcapsules were  
350 also prepared by using Ca-alginate hydrogel using emulsion extrusion method. For this  
351 alginate (20 g l<sup>-1</sup>) in deionized water, carvacrol & Tween 80 were added to a final  
352 concentration of 200 and 0.5 g l<sup>-1</sup> respectively. The mixture was emulsified using blender,  
353 emulsion was extruded into collecting water bath using 20 g l<sup>-1</sup> CaCl<sub>2</sub> in encapsulator with  
354 500 µm nozzle. The microcapsules kept for 30 minutes in CaCl<sub>2</sub> for hardening, washed and  
355 air dried for 30 h at 22°C. The microcapsules showed strong antimicrobial activity against  
356 *E.coli* in vitro and during in vitro digestion only 20% carvacrol released in gastric fluid while  
357 remaining in intestinal fluid after 6 hours of incubation.<sup>17</sup>

358 Co-crystallization is another method used for the encapsulation of orange peel oil. In  
359 this process crystal structure of sucrose is modified from a perfect crystal to conglomerate.



360 The resultant structure has porous configuration which can accept the addition of second  
361 ingredient. For orange peel oil sucrose syrup of 70<sup>0</sup> Brix was concentrated to 95<sup>0</sup> Brix under  
362 hot magnetic stirring, orange peel oil was added at variable ratios (100, 150, 170, 200 and  
363 250 g oil/kg sucrose) using shear mixer till crystallization achieved. When crystallization  
364 started, heating was stopped and heat of crystallization eliminated water to make granular  
365 product. The encapsulation efficiency of sucrose syrup was >90% and oxidized flavor were  
366 observed in formulations that have antioxidants prior to co-crystallization. This method is  
367 rarely used for the encapsulation of food ingredients due to lack of versatility and health  
368 concerns related to sucrose.<sup>90</sup> In the emulsion evaporation method,<sup>91</sup> poly (DL-lactide-co-  
369 glycolide) PLGA (50 mg) in dichloromethane (2 ml) with trans-cinnamaldehyde or eugenol  
370 (16% w/w) was prepared. After that aqueous phase containing poly vinyl alcohol (PVA:  
371 0.3% w/v) mixed with organic phase and oil in water (O/W) emulsion was prepared using  
372 homogenization. Further, emulsions were sonicated at 2°C for 10 minutes at 70w energy  
373 output and organic phase evaporated using rotary evaporator. Finally, nanoparticles loaded  
374 with eugenol and trans-cinnamaldehyde were purified through ultrafiltration and freeze dried.  
375 The nanoparticles were in the size range of 200 nm with encapsulation efficiency of both  
376 compounds ranging from 92-98% and were effective against *salmonella* and *Listeria* spp.  
377 These results favored encapsulation of EO using this approach because of its ability to protect  
378 and increased the shelf stability of encapsulated compound. Zein nanospheres loaded with  
379 thyme, cassia & oregano EO were prepared using phase separation method. For this each oil  
380 (250 mg) with zein (1 g) dissolved in ethanol (85%), solution was rapidly mixed with 0.01%  
381 silicone fluid till single phase formed and the opaque solution containing oil was lyophilized  
382 overnight. The nanospheres prepared were of irregular shape and the encapsulation  
383 efficiencies of oils were in the range of 65-75%. This technique is rapid, enabled protection  
384 of EOs and controlled its release in stomach, small intestine & large intestine.<sup>92</sup>

385 Emulsification external gelation method was used for the preparation of turmeric oil loaded  
386 nanocapsules.<sup>93</sup> Briefly, turmeric oil solution in ethanol (20mg/ml) was mixed with alginate  
387 solution (0.6 mg/ml) containing Tween 20 (1% /v) to prepare o/w emulsions. For gelification  
388 of oil droplets emulsions were combined with 0.67 mg/ml CaCl<sub>2</sub> solution under stirring and  
389 another polymer chitosan (0-0.6 mg/ml acetic acid) was subsequently added, oil loaded  
390 alginate-chitosan nanocapsules were equilibrated overnight and solvent was removed using  
391 rotary evaporator. The nanocapsules prepared were in the size range of 162-667 nm and were  
392 stable for 120 days under room temperature and 4°C. Yeast cell has been successfully used  
393 for the encapsulation of limonene. To carry out this, yeast cells cytoplasmic material was  
394 removed by plasmolyser, cells were washed with water, centrifuged and spray dried. Finally,  
395 yeast cells (80 g) were infused with limonene solution (9.1% w/w). The oil was successfully  
396 encapsulated as evident from transmission electron microscope (TEM) images and proved to  
397 be a suitable approach for the encapsulation of water soluble bioactives.<sup>68</sup>

### 398 3.5 Emulsifiers/wall materials used for essential oils

399 A variety of carbohydrate, proteins, and gums based emulsifiers or wall materials  
400 have been used for the encapsulation of EOs (Table 1). Among carbohydrates,  $\beta$ -cyclodextrin  
401 was used to prepare OEO loaded emulsions that were spray dried to obtain stable  
402 microcapsules having size in the range of 1.07-38  $\mu\text{m}$ .<sup>74</sup> Similarly a variety of researchers  
403 used  $\beta$ -cyclodextrin to prepare inclusion complex around hydrophobic EOs that protect them  
404 against oxidation, heat damage and increased their antibacterial efficacy for a longer time  
405 period.<sup>24,81,83,82</sup> Beirao-da-costa and others (2013)<sup>18</sup> used inulin as wall material for the  
406 encapsulation of OEO, microcapsules prepared were spherical (3-4.5  $\mu\text{m}$ ) and enabled  
407 sustained release of oil till 200 minutes. N-octenyl succinic anhydride modified (HI CAP  
408 100, Purity Gum 2000, Capsul & N-lock) and hydrolyzed starches (EnCapsul 855) used for  
409 the encapsulation of PO. Modified starches showed increased retention, better stability of oil

410 in spray dried powder<sup>30</sup> and nanoemulsions<sup>21</sup> (< 200 nm). Eugenol and Carvacrol were  
411 encapsulated by chitosan and Tripoly phosphate (TPP) ionic cross linking and the  
412 nanoparticles produced (217, 235 & 260 nm) showed better retention of compounds  
413 incorporated. Further, nanoparticles were stable for extended time period before and after  
414 incorporation of EO components.<sup>29</sup> Another research group encapsulated orange peel oil  
415 using sucrose syrup, the granular co-crystallizate showed 90% encapsulation efficiency and  
416 showed better protection against oxidation.<sup>90</sup> In case of proteins, gelatin was used to  
417 encapsulate citronella, thyme and rosemary oil, microcapsules (60 µm) prepared were  
418 spherical and exhibited controlled release of oil (10 hours).<sup>26,31</sup> Parris and others (2005)<sup>92</sup>  
419 encapsulated thyme, oregano and cassia oil using zein, nanoparticles prepared had an average  
420 diameter of 100 nm and showed oil yield from 65-75%. They reported less release of oil from  
421 zein nanospheres during in vitro digestion in stomach, slow release in small intestine and  
422 rapid release in large intestine. Soy lecithin (3%) and pea proteins (3%) have been used as  
423 emulsifiers for the encapsulation of Limonene, trans-cinnamaldehyde and *Malaleuca*  
424 *alternifolia* terpenes. The nanoemulsions prepared were stable in terms of particle size and  
425 had particle size in the range of 184-239 nm.<sup>28</sup> Corn oil nanoemulsions have also been  
426 prepared using sodium caseinate and β-lactoglobulin and were physically stable having  
427 particle diameter 150 nm.<sup>89</sup> Among gums acacia, gum arabic has been used for the  
428 encapsulation of ginger, basil and rosemary EO.<sup>77,94</sup> Gum arabic (1:4 w/w oil to wall ratio)  
429 emulsified emulsions of both oils exhibited low viscosity and particles prepared after spray  
430 drying showed retention of basil and rosemary oil (56.43-90.6%:7.15-47.57%), respectively.  
431 They also reported more loss of EO from larger droplets compared to smaller ones during  
432 spray drying due to longer time of film formation around droplets. Najafi and others (2011)<sup>80</sup>  
433 compared protein (skim milk powder) and carbohydrate (HI CAP 100) based wall material  
434 for the encapsulation of cardamom oil. They reported narrow droplets size (13.97-19.91 µm)

435 prepared from HI CAP 100 compared to skim milk powder (15.41-21.87  $\mu\text{m}$ ) and  
436 subsequently more loss of volatiles occurred in skim milk encapsulated powders.

437 In spite of individual use of protein/carbohydrate based emulsifiers or wall materials,  
438 mixtures of carbohydrate: protein, carbohydrate: gums and protein: gums have also been used  
439 to encapsulate EOs for better retention and protection. Fernandes and others (2014)<sup>79</sup> used  
440 whey protein isolate (WPI): Inulin blends for the encapsulation of rosemary EO. They  
441 reported better protection of oil particles in powder against oxidation due to low moisture  
442 content as WPI concentration in blend increased. WPI: Inulin blends (1:1 & 3:1) were the  
443 effective carriers for the entrapment of rosemary oil and had particle size in the range of 11.5-  
444 11.9  $\mu\text{m}$ . Similarly, WPI: maltodextrin maillard conjugates (1% /v) were used for the  
445 encapsulation of thymol oil,<sup>75</sup> microcapsules prepared were spherical having size in the range  
446 of 1-5  $\mu\text{m}$  and oil retention increased as concentration of maillard conjugates increased from  
447 1-11.1% w/v. Chatterjee and Bhattacharjee (2013)<sup>27</sup> used maltodextrin: gum arabic (12:6 g)  
448 mixture for the encapsulation of eugenol rich clove extract, microcapsules (1-15  $\mu\text{m}$ ) showed  
449 shrivelled morphology and maximum retention of eugenol was 65%. They reported increased  
450 percentage of carbohydrate (4.8) in relation to gum (2.4) that was effective in increasing the  
451 retention of oil.

452 In addition to above mentioned food grade emulsifiers/wall materials, variety of  
453 synthetic emulsifiers have also been used for the encapsulation of EOs. Sinico and others  
454 (2005)<sup>32</sup> used Brij30 (5.75 mg/ml) as surfactant for the synthesis of *A.aborescens* oil loaded  
455 liposomes. They reported lower retention of oil (66.09%) in niosomal bilayers prepared with  
456 Brij30 compared to phospholipid based liposome (74.15%). However, liposomes and  
457 niosomes were stable for one year when stored at 4 -5°C. The agglomeration of lemon grass  
458 oil microcapsules was overcome by the addition of 0.4wt% sodium dodecyl sulphate (SDS)  
459 due to repulsion mechanism as it is ionic surfactant.<sup>55</sup> Donsi and others (2011)<sup>28</sup> prepared D-

460 limonene & terpenes mixture from *Melaleuca alternifolia* based nanoemulsions using natural  
461 (soy lecithin, cleargum) and synthetic emulsifiers (glycerol monooleate with Tween 20).  
462 Nanoemulsions of terpenes, D-limonene prepared with soy lecithin had particle size (74 &  
463 240 nm) while tween20/glycerol monooleate based emulsions droplet diameter was (130-  
464 155nm). Moreover, all emulsions formulations were physically stable for a period of 4 weeks,  
465 showed no visible creaming and consistent particle diameter. Corn oil nanoemulsions  
466 prepared with synthetic emulsifiers (Tween 20 & SDS) showed smaller droplet size 60 nm  
467 while in case of sodium caseinate &  $\beta$ -lactoglobulin the particle size raised to 150 nm.  
468 However, later nanoemulsions were physically more stable than former ones.<sup>88</sup> Similarly  
469 Span 60,<sup>84</sup> Tween 80<sup>84,22</sup> & Tween 20, Montanov 82,<sup>89</sup> Triton x100<sup>87</sup> have been used to  
470 encapsulate EOs.

### 471 3.6 Encapsulation and its benefits

#### 472 3.6.1. Encapsulation of essential oils (EOs) for controlled release

473 Encapsulation represents a viable and efficient approach to increase the physical  
474 stability of EOs, protection from evaporation, and because of narrow size range enables  
475 controlled release & enhanced bioactivity. Chang and Daobashi (2003)<sup>66</sup> prepared eucalyptus  
476 oil loaded alginate, and calcium chloride complex capsules of 1- 2.5 mm, using interfacial  
477 insolubilization reaction. They showed controlled, slow release of eucalyptus oil after  
478 encapsulation as analyzed by using incubation and finger crash force technique. Briefly,  
479 capsules were placed in between the fingers and crashed; the crashing force was standardized  
480 by taking 10 volunteers (Chinese students) index finger readings. The force was measured,  
481 and determined as  $5.4 \times 10^6$  dyne. In another study, camphor oil was encapsulated to attain its  
482 sustained release, using complex coacervation method. Microcapsules of variable sizes  
483 (294.7 $\pm$ 14.2, 167.2 $\pm$ 11.2, 85.7 $\pm$ 8.7  $\mu$ m) at different homogenization speed 500, 1000 & 2000  
484 (rpm) were prepared. They observed that microcapsules prepared at 500 rpm & 0.75 oil/wall

485 ratio showed 99.6% (wt/wt) encapsulation efficiency. Moreover, they reported that camphor  
486 oil sustained release properties were directly dependent on cross linking agent called  
487 polystyrene.<sup>25</sup> Hosseini and others (2013)<sup>20</sup> reported controlled release pattern of oregano  
488 essential oil (OEO) loaded nanoparticles, prepared by using two step method that involves oil  
489 in water emulsion, and then ionic gelation of chitosan and tripolyphosphate (TPP). They  
490 observed rapid release of oil from smaller nanoparticles, and 82% of OEO released during 3  
491 hours even though at low concentration of OEO (0.1% w/w chitosan), but its release was  
492 slowed down at higher chitosan concentration (0.8% w/w), and reduced from 82% to 12%  
493 during 3 hours. Similarly, contrasting results were obtained when citronella oil was  
494 microencapsulated using chitosan, NaOH, and coconut oil as cosurfactant. They observed  
495 slow, and sustained release in microcapsules (225± 24 µm) that have larger size, and higher  
496 concentration of chitosan than smaller (131±20, 11±3µm) ones.<sup>15</sup> Moreover, slow release of  
497 neem oil (azadirachtin) loaded nanoemulsions based beads coated with gum arabic, and  
498 polyethylene glycol (PEG), having particle size in the range of 1.28±0.006 – 1.49±0.004mm  
499 have also been reported. They showed increased release of azadirachtin (44.2, 66.8, 79.4 &  
500 100%) from nanoemulsions after 6, 12, 18 and 24 hours. However, significant decrease in  
501 azadirachtin release from nanoemulsions (31.6, 40.45, 51.6 & 70.6% and 41.6, 54.2, 66.8,  
502 80.6%, respectively) was attained after being coated with gum arabic, and PEG. They  
503 concluded that gum arabic coating on nanoemulsions was better for controlled and slow  
504 release of azadirachtin than PEG.<sup>67</sup> Beirao-Da-Costa and others (2013)<sup>18</sup> also reported  
505 controlled release of OEO when encapsulated using inulin. The microcapsules prepared (3-  
506 4.5 µm) showed increased release of Oil during first 75 min but, later it became slow till 200  
507 min and after that lag phase appeared. Release of lavender oil was also controlled by  
508 encapsulating it in collagen hydrolysate, chitosan, and glutaraldehyde as cross linker. They  
509 observed slow release of lavender oil from microcapsules by increasing concentration of

510 chitosan, and cross linker. Protection of aroma compounds, and controlled release, and their  
511 increased bioavailability have also been confirmed by other researchers.<sup>19,68,69</sup>

### 512 3.6.2. Encapsulation of essential oils (EOs) for increased bioavailability

513 In addition to controlled release characteristics, various researchers have also reported  
514 increased bioavailability of EOs after encapsulation in variable matrices. For example, Liang  
515 and others (2012)<sup>21</sup> encapsulated peppermint oil (PO) in starch based nanoemulsions to  
516 increase its stability, and bioavailability. The nanoemulsions with particle size of 200 nm  
517 showed enhanced bactericidal activity against *L.monocytogenes*, and *S.aureus* compared to  
518 bulk PO. This was attributed to greater solubility, and more availability due to subcellular  
519 size of particles. Similarly, increased bactericidal action due to more absorption of  
520 D.limonene, carvacrol, eugenol, and cinnamaldehyde by *L.delbrueckii*, *S.cerevisiae*, and  
521 *E.coli* cells from nanoemulsion has also been reported.<sup>28, 22,70</sup> Increased absorption of EOs  
522 after encapsulation lowered the amount of oil required to kill microorganisms. Meanwhile,  
523 increased bactericidal action of OEO attained at  $25.0 \times 10^{-8}$  g/ml, when incorporated in  
524 liposome and this quantity was equivalent to  $6.0 \times 10^{-3}$  g/ml unencapsulated OEO. These  
525 results showed enhanced bactericidal activity of OEO in liposomes against human pathogenic  
526 bacteria (*S.aureus*, *S.epidermidid*, *S.mutans*, *S.viridans*, *P.aeruginosa*, *E.coli*, *E.cloacae*,  
527 *K.pneumonia*), fungi (*C.albicans*, *C.tropicalis*, *C.glabrata*) and food borne pathogen  
528 (*L.monocytogenes*) because of increased uptake/bioavailability by living cells.<sup>71</sup> Increased  
529 absorption of EOs in nanoemulsions by bacterial cells *S.aureus*, *B.cereus*, *E.coli* and  
530 *P.mirabilis* has also been reported by other researchers.<sup>72,73</sup>

531 In addition to increased absorption of EOs by bacterial cells, *A. aborescens* EO loaded  
532 unilamellar (78±11, 104±19, 123±21nm) and multilamellar liposomes (232±25,  
533 252±29,304±21nm) also showed increased antiviral potential against herpes simplex 1 (HSP)

534 virus due to increased absorption after encapsulation. They confirmed poor antiviral activity  
535 of unencapsulated, and unilamellar liposomes incorporated *A.aborescens* EO at 100 µg/ml.  
536 However, antiviral activity significantly increased when it was incorporated in multilamellar  
537 liposomes and EC50 value reduced to 18.5 µg/ml.<sup>32</sup>

### 538 3.6.3. Encapsulation of essential oils (EOs) for increased stability

539 Encapsulation not only provides controlled release, and improved bioaccessibility of  
540 EOs but, also increased their stability<sup>21,22,28,70</sup> as they are susceptible to conversion and  
541 degradation after exposure to environmental stresses<sup>97</sup> as shown in Figure II. Various  
542 researchers reported increased bioactivities (antimicrobial & antiproliferative) of EOs in  
543 encapsulation matrix compared to free oil even at same or lower concentration, that suggests  
544 their resistance against conversion (oxidation, isomerization, polymerization, thermal  
545 rearrangements etc.) and degradation<sup>17,22,70</sup>. For example, Liang and others<sup>21</sup> prepared  
546 peppermint oil (PO) loaded nanoemulsions, and observed decrease (5 %) in main constituent  
547 of PO (menthol) after quantification using GC-MS compared to PO. In spite, of decrease in  
548 main constituent of PO, the nanoemulsions showed enhanced and long term bactericidal  
549 growth inhibition against *L. monocytogenes* and *S. aureus* compared to free PO even at same  
550 MIC value. These results suggest the better stability of EOs after encapsulation. Similarly,  
551 other researchers<sup>28,98</sup> also reported greater bactericidal activities of EOs in nanoemulsions  
552 based encapsulation system, even after minimal losses of their constituents during processing.  
553 On the other hand, carvacrol loaded calcium alginate microcapsules showed better stability,  
554 when passed through gastrointestinal digestion model. Further, retention of carvacrol  
555 antimicrobial activity against *E.coli* after intestinal digestion of microcapsules suggests  
556 encapsulation being a suitable approach to prevent EOs from degradation and conversion.<sup>17</sup>  
557 Similarly, *Ocimum basicilicum* and *Oreganum vulgare* EOs showed better stability against  
558 degradative action of oxygen and temperature, when encapsulated in β-cyclodextrin inclusion



559 complex and microparticles<sup>99,100</sup>. Moreover, the better retention, and increased protection of  
560 EOs in colloidal matrix depends on the type, and parameters of technique/procedure used that  
561 ultimately affect the bioavailability, and controlled release of active compound.

#### 562 **4. Encapsulated essential oils applications**

563 Encapsulated EOs have been used in vitro and in vivo applications for food by many  
564 researchers. Liang and others (2012)<sup>21</sup> used PO loaded nanoemulsions (0.25% v/v) to inhibit  
565 the growth of food borne pathogens *L.monocytogenes* and *S.aureus*. They observed long term  
566 inhibition of bacterial growth when treated with PO nanoemulsions even though MIC values  
567 of both bulk oil and PO nanoemulsions were same. Similarly, eugenol & carvacrol loaded  
568 nanoemulsions (800 ppm) were also used to inhibit the growth of *E.coli* & *L.innocua* and  
569 strong inhibition occurred with emulsions having droplet size 3000 nm. Improved  
570 bactericidal action (*E.coli*, *L.delbrueckii* & *S.cerevisiae*) of carvacrol, cinnamaldehyde and  
571 D-limonene nanoemulsions has also been reported.<sup>28</sup> In vitro application of OEO loaded  
572 microcapsules against *E.coli* (0.20-0.05), *S.aureus* (0.10-0.05) and *P.aeruginosa* (0.20-0.10)  
573 decreased minimum bactericidal concentration of OEO two to fourfold compare to pure oil.  
574 They also reported four-eightfold increase in antiradical activity after encapsulation.<sup>74</sup>  
575 Similarly, increased antibacterial potential was also observed when eugenol and carvacrol  
576 grafted nanoparticles were used against *E.coli* & *S.aureus*.<sup>29</sup> Growth of food borne pathogens  
577 (*Salmonella* & *Listeria* spp) was also reduced to a greater extent when exposed to eugenol  
578 and trans-cinnamaldehyde loaded nanoparticles (10-20 mg/ml).<sup>91</sup> OEO loaded liposomes  
579 caused growth inhibition of gram positive (*S.aureus*, *epidermidis*, *mutans* & *viridians*), gram  
580 negative (*E.coli*, *E.cloacae*, *k.pneumoniae* & *P.aeruginosa*), three human fungal pathogens  
581 (*C.albicans*, *glabrata* & *tropicalis*) and *L.monocytogene* at concentration  $25.0 \times 10^{-8}$  g/ml  
582 that was equivalent to unencapsulated  $6 \times 10^{-3}$  g/ml.<sup>71</sup> The results of this study showed  
583 encapsulated EOs are better to use in food and other applications to overcome the challenge

584 of sensory attributes variation that happened due to the use of higher EO concentrations. In  
585 addition to above mention in vitro applications encapsulated EOs have also been used in vivo  
586 as natural preservative to increase the shelf life. Donsi and others (2011)<sup>28</sup> used *Melaleuca*  
587 *alternifolia* loaded nanoemulsions in orange and pear juices to extend the shelf life of juices.  
588 The nanoemulsions with variable terpenes concentrations of 5 g/l, 10 g/l completely inhibited  
589 the initial microbial (*L.delbrueckii*) load  $10^3$  CFU/ml whereas, 1 g/l only delayed bacterial  
590 growth till 5 days in orange juice and 2 days in pear juice compared to control. Similarly,  
591 nano-dispersed eugenol was also used to increase the shelf life of milk (4% fat, 2% fat &  
592 skimmed milk <0.5% fat). Nanodispersed eugenol completely inhibited bacterial growth of  
593 *E.coli* at 3.5 g/l, while 4.5 g/l was not effective to inhibit the bacterial growth in full fat milk.  
594 However, 5.5 g/l completely inhibited bacterial growth of *E.coli* in all milk types. In case of  
595 *L.monocytogenes* nano-dispersed eugenol at 5.5 g/l concentration was not effective as against  
596 *E.coli* but, showed better efficacy than free eugenol and reduced bacterial growth in full fat  
597 milk to 2.6 log CFU/ml and 5.5 log CFU/ml in case of free eugenol.<sup>76</sup>

598 In order to control herpes simplex virus1 (HSP1), *Artemesia arborescens* EO loaded  
599 liposomes showed excellent alternative to drugs. Liposomes inhibited HSP1 growth at EC50  
600 dose of 5.95 µg/ml that was equivalent to 100 µg/ml of free EO.<sup>32</sup> Nuchuchua and others  
601 (2009)<sup>89</sup> reported prolonged action of citronella, basil and vetiver oil nanoemulsions against  
602 *Aedes aegypti* both in vivo and in vitro. Nanoemulsions applied to  $3 \times 10$  cm<sup>2</sup> area of human  
603 skin, well spreaded due to small droplet size (50-220 nm) and increased the protection time to  
604 4.7 hours (basil:vetiver:citronella 5:5:10 w/w%). In another study, carvacrol loaded  
605 microcapsules (calcium alginate) used to control the enteric diseases in pig. In vitro release  
606 study of microencapsulated carvacrol showed limited release in stomach, slow release in  
607 small intestine and more release in large intestine. However, in vitro antibacterial test showed  
608 similar minimum bactericidal concentration (200 µl/l) of both free and encapsulated carvacrol

609 against *E.coli* with K88 pili.<sup>17</sup> Moretti and others (2002)<sup>96</sup> used thymus and rosemary oil  
610 loaded nanoemulsions against *Limantria dispar*, a cork oak forest pest. They reported 100%  
611 mortality rate after emulsions treatment till 7 hours.

612 Improved bioactivity of liposomes encapsulated *Myrtus communis* extract was  
613 reported by<sup>14</sup> when incorporated in sunflower oil at concentration of (160 ppm), the  
614 encapsulated extract showed 25% higher oxidation protection factor (1.5 after incubation of  
615 29.5h) compared to free extract (1.2 after incubation of 23.5h). However, liposomes  
616 encapsulation concentration was not equivalent to free extract. They also confirmed  
617 antioxidant potential of liposomes encapsulated *Myrtus communis* in terms of onset of thermo  
618 oxidation process using differential scanning calorimetry (DSC) and the temperature ranges  
619 for control, free extract & liposome encapsulated extract were 218, 237 and 272°C,  
620 respectively. In case of soybean oil the microencapsulated eugenol rich clove extract powder  
621 showed similar antioxidant protection values ( $0.085 \pm 0.006$ ) as observed in BHT and  
622 unencapsulated clove extract. On the other hand both BHT and unencapsulated clove extract  
623 showed pro-oxidant activity due to excessive antioxidants in soybean oil that degrade linoleic  
624 acid and ultimately forms free radicals by the decomposition of hydrogen peroxide. However,  
625 encapsulated clove extract incorporated soybean oil showed no pro-oxidant activity and  
626 therefore, recommended to use as natural antioxidant in food rather synthetic ones.<sup>27</sup>

## 627 **5. Encapsulated essential oils behaviours/trends**

628 The composition of PO in purity gum 2000 based nanoemulsions before and after  
629 encapsulation using high pressure homogenization was quantified to interpret the loss of oil  
630 constituents during processing. They reported quite similar composition of pure and  
631 encapsulated PO.<sup>21</sup> Sweet orange oil microencapsulated by complex coacervation (soybean  
632 protein isolate: gum Arabic mixture) method also showed complete retention of flavour

633 compounds in microcapsules as in pure oil (D-limonene 89.5% in pure & 90.97% in  
634 microcapsules.<sup>95</sup> Similarly, Arana-sanchez and others (2010)<sup>74</sup> also reported no degradation  
635 of OEO components when emulsions were spray dried and analysed using GC-MS. The  
636 percentage composition of OEO constituents pure & extracted from microcapsules were quite  
637 similar (P-cymene 34.68- 34.66%, Thymol 9.42-19.52% & carvacrol 7.34-7.36%,  
638 respectively. Moretti and others (2002)<sup>96</sup> also confirmed similar profile of thymus and  
639 rosemary EO constituents before and after encapsulation. However, terpenes mixture of  
640 *Melaleuca alternifolia* was quantified using GC-MS after processing through high shear and  
641 high pressure homogenizer.<sup>70</sup> They observed degradation of active compounds ( $\alpha$ -felandrene  
642 1.50-0.36, terpinolene 10.03-1.21, carvacrol 4.31-0.50 g/kg). In another study, changes in the  
643 composition of PO constituents were observed when liquid emulsified and spray dried  
644 products were analysed using GC & GC-MS.  $\beta$ -pinene was decreased 2-3 times compared to  
645 pure EO and percentage of oxygenated terpenol menthol increased in processed products  
646 from 47.5-50.1%.<sup>30</sup> Gaysinsky and others (2005)<sup>97</sup>, reported temperature stability of micellar  
647 encapsulated eugenol & carvacrol. They observed with increased eugenol concentration in  
648 micelle, the temperature stability decreased i.e, at 0.1% eugenol the micelles were stable at  
649 90°C but at 0.9% eugenol the micelles were stable at 60°C. Eugenol encapsulated in  $\beta$ -  
650 cyclodextrin, 2HP-  $\beta$ -cyclodextrin & PCL using molecular inclusion and emulsion diffusion  
651 method showed irradiation induced stability as evident by TGA after 60 days of storage under  
652 light and without light in desiccator at 25°C. Both  $\beta$ -cyclodextrin-eugenol, 2HP-  $\beta$ -  
653 cyclodextrin-eugenol complexes after O<sub>2</sub> injection during TGA analysis showed significant  
654 weight gain (7.9 & 15.2%) at 20-150°C and it was attributed to free oxidation reaction  
655 occurred from free eugenol with oxygen that injected as purged gas.<sup>24</sup> In the emulsion ionic  
656 gelation of OEO (carvacrol), improved thermal stability was confirmed after encapsulation at

657 elevated temperature of 340.6°C.<sup>20</sup> The result from this study favours the use of encapsulated  
658 EOs in various food applications even at elevated temperature during processing.

## 659 **6. Conclusions and Future Perspectives**

660 Encapsulation is therefore an efficient approach to protect the EOs from light, air and  
661 humidity, because these interactions lead to oxidation or volatilization and reduced biological  
662 activities. Moreover, encapsulation increases the solubility of oil, provides controlled release  
663 and makes it more bioavailable. Spray drying and emulsification are the most versatile and  
664 commercially available techniques that had been used widely for EOs encapsulation. The  
665 encapsulated EOs showed enhanced antimicrobial, antifungal, antioxidant, antiviral and  
666 pesticidal activities. The use of encapsulated EOs in food, cosmetic and pharmaceuticals could  
667 be an economic benefit and also fulfill the consumer concern regarding safety. The use of  
668 encapsulated EOs in cosmetics and pharmaceuticals is lacking. Further, research is required to  
669 underpin recent analytical approaches in order to gain deeper understanding of oxidation,  
670 isomerization and thermal rearrangements processes and strategies to avoid them. Moreover,  
671 identification of products generated from these processes appears to be a valuable future  
672 objective. Further, encapsulated EOs can be used to increase the bioactivities of EOs in real  
673 food systems, to study their action mechanism on cell membranes, and to provide non-lethal  
674 therapeutic agents to treat several diseases.

## 675 **Acknowledgements:**

676 This work was financially supported by National 863 Program 2011BAD23B02,  
677 2013AA102207, NSFC 31171686, 30901000, 111 project-B07029 and PCSIRT0627.

## 678 **References:**

679 1 A.E. Edris, *Phytotherapy Research*, 2007, 21, 308–323.

- 680 2 H.J.D. Dorman and S.G. Deans, *Journal of Applied Microbiology*, 2000, 88, 308-316.
- 681 3 S.F.A. Jones, *European Journal of Gastroenterology and Hepatology*, 1996, 8,
- 682 1227-1231.
- 683 4 M. LisBalchin and S.G. Deans, *Journal of Applied Microbiology*, 1997, 82, 759-762.
- 684 5 S. Moon, H. Kim and J. Cha, *Archives of Oral Biology*, 2011, 56, 907-916.
- 685 6 Y. Fu, Y. Zu, L. Chen, X. Shi, Z. Wang and S. Sun, *Phytotherapy Research*, 2007, 21,
- 686 989-994.
- 687 7 B. Joseph and S. Sujatha, *Asian Journal of Biological Sciences*, 2011, 4, 35-43.
- 688 8 E.S. Walsh, Y.J. Maillard, D.A. Russell, E.C. Catrenich, L.D. Charbonneau and G.R.
- 689 Bartolo, *Journal of Applied Microbiology*, 2003, 94, 240-247.
- 690 9 M.L. Al-hadi, *Journal of Bagh College Dentistry*, 2011, 23, 146-50.
- 691 10 K. Fisher and A.C. Phillips, *Journal of Applied Microbiology*, 2006, 101, 1232-1240.
- 692 11 W.J.R. Lambert, P.N. Skandamis, P.J. Coote and G.J.E. Nychas, *Journal of Applied*
- 693 *Microbiology*, 2001, 91, 453-462.
- 694 12 Y.S. Lee and H.H. Jin, *Letters in Applied Microbiology*, 2008, 47, 315-321.
- 695 13 V.F.S. Vuuren, S. Suliman and M.A. Viljoen, *Letters in Applied Microbiology*, 2009,
- 696 48, 440-446.
- 697 14 O. Gortzi, S. Lalas, L. Chinou and J. Tsaknis, *European Food Research Technology*,
- 698 2008, 226, 583-590.
- 699 15 W. Hsieh, C. Chang and Y. Gao, *Colloids and surface B: Biointerfaces*, 2006, 53,
- 700 209-214.
- 701 16 B. Ocak, *Journal of Environmental Management*, 2012, 100, 22-28.
- 702 17 Q. Wang, J. Gong, X. Huang, H. Yu and F. Xue, *Journal of Applied Microbiology*,
- 703 2009, 107, 1781-1788.

- 704 18 S. Beirao-da-costa, C. Duarte, A.I. Bourbon, A.C. Pinheiro, M.I.N. Januario, A.A.  
705 Vicente, M.L. Beirao-da-costa and I.D. Dillo, *Food hydrocolloids*, 2013, 33, 199-206.
- 706 19 A. Ciobanu, I. Mallard, D. Landy, G. Barbie, D. Nistor and S. Fourmentin, *Food*  
707 *Chemistry* 2013, 138, 291-297.
- 708 20 F.S. Hosseini, M. Zandi, M. Rezaei and Farahmndghavi, *Carbohydrate Polymers*,  
709 2013, 95, 50-56.
- 710 21 R. Liang, S. Xu, C.F. Shoemaker, Y. Li, F. Zhong and Q. Huang, *Journal of*  
711 *Agriculture and Food Chemistry*, 2012, 60, 7548-7555.
- 712 22 N. Terjung, M. Loeffler, M. Gibis, J. Hinrichs and J. Weiss, *Food Function*, 2012, 3,  
713 290–301.
- 714 23 F.J. Ayala Zavala, H. Soto-valdez, G.A. Lez-leo, A.E. Ivarez-parrilla, O. Maartin-  
715 Belloso and G.A.G. Lez-agular, *Journal of inclusion phenomenon Macrocyclic*  
716 *chemistr*, 2008, 60, 359-368.
- 717 24 M. Choi, A. soottitawat, O. Nuchuchua, S. Min and U. Ruktanonchai, *Food*  
718 *research international*, 2009, 42:148-156.
- 719 25 C. Chang, T. Leung, S. Lin and C. Hsu, *Colloids and Surfaces B: Biointerfaces*, 2006,  
720 50, 136-140.
- 721 26 S.G. Passino, E. Bazzoni and L.D.M. Moretti, *Veg. Plagas*, 2004, 30, 125-132.26.
- 722 27 D. Chatterjee and P. Bhattacharjee, *Journal of food engineering*, 2013, 117:545-  
723 550.27.
- 724 28 F. Donsi, M. Annunziata, M Sessa and G. Ferrari, *LWT–Food Science and*  
725 *Technology*, 2011, 44, 1908–1914.
- 726 29 F. Chen, Z. Shi, G.K. Neoh and T.E. Kang, *Biotechnology and Bioengineering*, 2009,  
727 104:30-39.

- 728 30 R. Baranauskiene, E. Bylaite, J.Z. Ukauskaite and R.P. Venskutonis, *Journal of*  
729 *agricultural food chemistry*, 2007, 55, 3027-3036.
- 730 31 B. Solomon, F.F. Sahle, T. Gebre-Mariam, K. Asres and H.H.R. Neubert, *European*  
731 *journal of Pharmaceutics and Biopharmaceutics*, 2012, 80, 61-66.
- 732 32 C. Sinico, D.A. Logu, F. Lai, D. Valenti, M. Manconi, G. Loy, L. Bonsignore and  
733 M.A. Fadda, *European journal of Pharmaceutics and Biopharmaceutics*, 2005, 59,  
734 161-168.
- 735 33 Y.S. Lee and HH. Jin, *Letters in Applied Microbiology*, 2008, 47, 315-321.
- 736 34 Y. Fu, Y. Zu, L. Chen, X. Shi, Z. Wang and S. Sun, *Phytotherapy Research*, 2007, 21,  
737 989-994.
- 738 35 P. Chuang, C. Lee, J. Chou, M. Murugan, B. Shieh and H. Chen, *Bioresource*  
739 *technology*, 2007, 98, 232-236.
- 740 36 M.L. Grbic, M. Stupar, J. Vukojevic, M. Sokovic, D. Mistic, D. Grubisic and M.  
741 Ristic, *Journal of Serbian chemical society*, 2008, 73, 961-965.
- 742 37 E.N. Pinto, C.L. Pinavaz, L.G. Salgueiro, M.J. Goncalves, S. Costadeoliveira, C.  
743 Cavaleiro, A. Palmeira, A.C. Rodrigues and J. Martinezdeoliveira, *Journal of medical*  
744 *microbiology*, 2006, 55, 1367-1373.
- 745 38 S. Siripornvisal, W. Rungprom and S. Sawatdikarn, *Asian journal of food and agro*  
746 *industry*, 2009, 5, 229-233.
- 747 39 S.R. Sridhar, R.V. Rajagopal, R. Rajavel, S. Masilamani and S. Narasimhan, *Journal*  
748 *of agricultural food chemistry*, 2003, 51, 7596-7599.
- 749 40 M. Viudamartos, Y. Ruiznavajas, J. Fernandezlopez and J.A. Perezalvarez, *Journal of*  
750 *food safety*, 2006, 27, 91-101.
- 751 41 S. Wang, P. Chen and S. Chang, *Bioresource Technology*, 2005, 96, 813-818.
- 752 42 S. Bansod and M. Rai, *World journal of Medical Sciences*, 2008, 3, 81-88.



- 753 43 A. Amiri, R. Dugas, L.A. Pichot and G. Bompeix, *International Journal of Food*  
754 *Microbiology*, 2008, 126, 13-9.
- 755 44 H. Amiri, *Evidence based Complementary and Alternative Medicine*, 2012, DOI 10.  
756 1155/2012/728065.
- 757 45 I. Goze, A. Alim, A.S. Tepe, M. Sokmen, K. Sevgi and B. Tepe, *Journal of medicinal*  
758 *plants research*, 2009, 3, 246-254.
- 759 46 M. Ennajar, J. Bouajila, A. Lebrihi, F. Mathieu, M. Abderraba, A. Raies and M.  
760 Romdhane, *Journal of food science*, 2009, 74.
- 761 47 I. Hammami, M.A. Triki and A. Rebai, *Archives of applied science research*, 2011, 3,  
762 135-144.
- 763 48 G. Miguel, M. Simoes, A.C. Figueiredo, J.G. Barroso, L.G. Pedro and L. Carvalho,  
764 *Food Chemistry*, 2004, 86, 183-188.
- 765 49 M.A. Saleh, S. Clark, B. Woodard, and S.A. Deolu-sobogun, *Ethnicity and disease*,  
766 2010, 20, 78- 82.
- 767 50 M. Vishnupriya, S. Nishaa, J.M. Sasikumar, P.D.D. Teepica, C.P. Hephzibah and  
768 V.K. Gopalakrishnan, *International research journal of pharmacy* 2012, 3, 99-103.
- 769 51 M. Viuda-martos, Y.R. Navajas, E.S. Zapata, J. Fernandez-lopez and A. Perez-  
770 alvarez, *Flavour and fragrance journal*, 2010, 25, 13-19.
- 771 52 I. Bettaieb, S. Bourgou, W.A. Wannes, I. Hamrouni, F. Limam and B. Marzouk,  
772 *Journal of Agricultural food chemistry*, 2010, 58, 10410-10418.
- 773 53 V. Dwivedi, R. Shrivastava, S. Hussain, C. Ganguly and M. Bharadwaj, *Asian pacific*  
774 *journal of cancer prevention*, 2011, 12, 1989-1993.
- 775 54 S.K. Jaganathan, A. Mazumdar, D. Mondhe and M. Mandal, *Cell biology*  
776 *international*, 2011, 35, 607-615.

- 777 55 H.P.A. Mary, T.A. Vargheese, K.J.J. Jeeja, M.R. Abiramy, N. Sajina and S.S. jaya,  
778 International journal of current pharmaceutical review and research, 2012, 2.
- 779 56 X. Ni, M.M. Suhail, Q. Yang, A. Cao, K. Fung, R.G. Postier, C. Woolley, G. Young,  
780 J. zhang and H. Lin, Complementary and alternative medicine, 2012, 12, 53.
- 781 57 A. Ozkan and A. Erdogan, Turk journal of biology, 2011, 35, 735-742.
- 782 58 A. Salazar, J. Hoheisel, M. Youns and M. Wink, International journal of clinical  
783 pharmacology and therapeutics, 2011, 49:93-95.
- 784 59 P.R. Sharma, D.M. Mondhe, S. Muthiah, H.C. Pal, A.K. Shahi, A.K. Saxena and G.N.  
785 Qazi, Chemico-Biological Interactions, 2009, 179, 160-168.
- 786 60 Y. Zu, H. Yu, L. Liang, Y. Fu, T. Efferth, X. Liu and N. Wu, Molecules, 2010, 15,  
787 Doi:10.3390.
- 788 61 S. Afoulous, H. Ferhout, E.G. Raelison, A. Valentin, B. Moukarzel, Couderc, C  
789 Francois and J. Bouajila, Food and chemical toxicology, 2013, 56, 352-62.
- 790 62 A. Russo, C. Formisano, D. Rigano, F. Senatore, S. Delfine, V. Cardile, S. Rosselli  
791 and M. Bruno, Food and chemical toxicology, 2013, 55, 42-47.
- 792 63 J. Yu, J. Lei, X. Zhang, H. Yu, D. Tian, Z. Liao and G. Zou, Food chemistry, 2011,  
793 12, 1593-1598.
- 794 64 M. Sylvestre, A. Pichette, A. Longtin, F. Nagaub and J. Legault, Journal of  
795 Pharmacology, 2006, 103, 99-102.
- 796 65 H.M. Ashour, Cancer Biology and Therapy, 2008, 7, 399-403.
- 797 66 C.P. Chang and T. Dobashi, Colloids and Surfaces B: Biointerfaces, 2003, 32, 257-  
798 262.
- 799 67 J. Jerobin, R.S. Sureshkumar, H.C. Anjali, A. Mukherjee and C. Natarajan,  
800 Carbohydrate polymers, 2012, 9, 1750-1756.

- 801 68 G. Dardelle, V. Normand, M. Steenhoudt, B. Pierre-Etienne, M. Chevalier and B.  
802 Pauline, *Food Hydrocolloids*, 2007, 21, 953-960.
- 803 69 V.D. Ramesh, *Trends Biomaterial and artificial organs*, 2009, 23, 21-33.
- 804 70 F. Donsi, M. Annunziata, M. Vincensi and G. Ferrari, *Journal of Biotechnology*,  
805 2012, 159, 324-350.
- 806 71 C.C. Liolis, O. Gortzi, S. Lalas, J. Tsaknis and I. Chinou, *Food Chemistry* 2009, 112,  
807 77-83.
- 808 72 S. Saryana, N. Chandrasekaran and A. Mukherjee, *International journal of pharmacy*  
809 *and pharmaceutical sciences*, 2012, 4, 668-671.
- 810 73 S. Sugumar, V. Ghosh and M.J. Nirmala, *Ultrasonic Sonochemistry*, 2014, 21, 1044-  
811 1049.
- 812 74 A. Aranaa-Sanchez, E.M. Espinosa, N.E. Obledo-Vazquez, E. Padilla-Camberos, R.  
813 Silva-Vazquez and E. Lugo-Cervantes, *Letters in Applied Microbiology*, 2010, 50,  
814 585-90.
- 815 75 B. Shah, M.P. Davidson and Q. Zhong, *International journal of food microbiology*,  
816 2012, 161, 53-59.
- 817 76 B. Shah, S. Ikeda, M.P. Davidson and Q. Zhong, *Journal of food engineering*, 2012,  
818 113, 79-85.
- 819 77 B.V.R. Fernandes, V.S. Borges, A.D. Botrel, K.E. Silva, G.M.J. Costa and F.  
820 Queiroz, *Drying Technology*, 2013, 31, 1245-1254.
- 821 78 B.V.R. Fernandes, V.S. Borges and A.D. Botrel, *Carbohydrate polymers*, 2014, 101,  
822 524-532.
- 823 79 N.M. Najafi, R. Kadkhodae and A.S. Mortazavi, *Food Biophysics*, 2011, 6, 68-76.
- 824 80 A.E.A. El-kader and S.F. Aggor, *Journal of Applied sciences Research*, 2013, 9,  
825 2951-2958.

- 826 81 I. Padukka, B. Bhandari and B. Darcy, *Journal of food composition and analysis*,  
827 2000, 13, 59-70.
- 828 82 E.L. Hill, C. Gomes and M.T. Taylor, *LWT- Food Science and Technology*, 2013, 51,  
829 86-93.
- 830 83 S. Rodriguez, S. Varona, M. Nunez and J.M. Cocero, *Industrial crops and products*,  
831 2012, 37, 137-140.
- 832 84 Y. Chang, L. McLandsborough and J.D. McClements, *Journal of Agriculture Food*  
833 *Chemistry*, 2012, 60, 12056-12063.
- 834 85 A. Achouri, Y. Zamani and I.J. Boye, *Journal of Food Research*, 2012, 1, 254-67.
- 835 86 T. Hamouda and R.J. Baker, *Journal of Applied Microbiology*, 2000, 89, 397-403.
- 836 87 C. Qian and J.D. McClements, *Food Hydrocolloids*, 2011, 25, 1000-1008.
- 837 88 O. Nuchuchua, U. Sakulku, N. Uawwongyart, S. Puttipipatkachorn, A.  
838 Soottitantawat and U. Ruktanonchai, *American Association of Pharmaceutical*  
839 *scientists*, 2009, 10, 1234-1242.
- 840 89 I.C. Beristain, A. Vazquez, S.H. Garcia and J.E. Vernon-carter, *Lebensm-wiss*  
841 *Technology*, 1996, 29, 645-647.
- 842 90 C. Gomes, G.R. Moreira and E. Castell-Perez, *Journal of food science*, 2011, 76, 16-  
843 24.
- 844 91 N. Parris, H.P. Cooke and B.K. Hicks, *Journal of Agricultural and Food Chemistry*,  
845 2005, 53, 4788-4792.
- 846 92 P. Lertsutthiwong, P. Rojisitthisak and U. Nimmannit, *Materials Science and*  
847 *Engineering*, 2009, 29, 856-860.
- 848 93 M.L. Kadam, S.I. Hashmin and R.V. Kale, *journal of environmental, agricultural and*  
849 *food chemistry*, 2011, 10, 2382-2390.
- 850 94 X. Jun-xia, Y. Hai-yan and Y. Jian, *Food Chemistry* 2011, 125, 11267-1272.

- 851 95 L.D.M. Moretti, G. Sanna-Passino, S. Demontis and E. Bazzoni, *Pharmaceutical*  
852 *science and technology*, 2002, 3, 1-11.
- 853 96 P. M. Gaysinsky, B. D. Davidson and J. B. Weiss, *Journal of food protection*, 2005,  
854 68, 2559-2566.
- 855 97 C. Turek and F. C. Stintzing, *Comprehensive reviews in food science and safety*.  
856 2013, 12, 40 – 53.
- 857 98 H. Majeed, J. Antoniou, C. F. Shoemaker, and Z. Fang, *Archives of Microbiology*.  
858 2014, 197, 35 – 45.
- 859 99 A. A. C. T. Hijo, J. M. G. D. Costa, E. K. Silva, V. M. Azevedo, M. I. Yosnida and S.  
860 V. Borges, *Journal of Food Process Engineering*. 2014, 38, 1-10.
- 861 100 D. I. Hadaruga, N. G. Hadaruga, C. I. Costescu, I. David and A. T. Grucia, *Beilstein*  
862 *journal of organic chemistry*. 204, 10, 2809 – 2820.
- 863
- 864